

24th January, 2012

Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai – 400 001

AJANTA HOUSE
Charkop, Kandivli (W),
MUMBAI - 400 067. INDIA
Tel. : (+91)22-6606 1000
Fax : (+91)22-6606 1200 / 300
E-mail : info@ajantapharma.com
Website : www.ajantapharma.com

Dear Sir,

Re: Clause 41
Scrip Code: BSE – AJANTAPH 532331
NSE – AJANTPHARM EQ

Pursuant to Clause 41 of the Listing Agreement, we are enclosing herewith Unaudited Financial Results for the third quarter ended 31st December, 2011 duly signed by the Managing Director. These results were approved by the Board of Directors at their Meeting held on Tuesday, 24th January, 2012.

We are also enclosing a copy of the Press Release to be published in newspapers.

Kindly acknowledge receipt.

Thanking You,

Yours faithfully,
For **AJANTA PHARMA LIMITED**



DEODATTA PANDIT
G.M. - Legal &
Company Secretary

Encl.: a/a

c.c. : National Stock Exchange of India,
Exchange Plaza, 5th Floor, Plot no. C/1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai – 400 051.

ajanta pharma limited

Regd. Office: 'Ajanta House', Charkop, Kandivli (W), Mumbai-67

Standalone Financial Results for the quarter ended 31st December, 2011

Particulars	3 months ended			9 months ended		₹ in Lacs
	31/12/2011	30/09/2011	31/12/2010	31/12/2011	31/12/2010	Year Ended 31/03/2011
	Unaudited			Unaudited		Audited
1. Net Sales/Income from Operations	16,389.90	13,512.91	12,050.50	42,633.58	33,129.79	45,714.56
2. Expenditure						
a. (Increase)/decrease in stock in trade and work in progress	(62.41)	(1,008.78)	1,993.02	(1,414.82)	685.01	537.37
b. Consumption of raw & packing materials	5,061.91	4,825.22	2,871.62	13,958.80	10,332.50	14,319.53
c. Purchase of traded goods	516.89	480.22	578.44	1,444.49	1,699.16	2,396.01
d. Employees cost	2,005.36	1,785.95	1,475.23	5,600.34	4,196.13	5,909.93
e. Depreciation	816.69	762.67	622.17	2,243.66	1,724.25	2,378.80
f. Research & Development Expenses	954.73	951.89	765.91	2,902.46	1,782.04	2,488.37
g. Other expenditure	4,538.38	4,156.37	2,087.01	12,317.06	8,278.20	11,108.47
h. Total	13,831.55	11,953.54	10,393.40	37,051.99	28,697.29	39,138.48
3. Profit from operations before Other Income, Interest & Exceptional Items	2,558.35	1,559.37	1,657.10	5,581.59	4,432.50	6,576.08
4. Other Income	62.31	24.16	68.20	263.62	124.72	164.96
5. Profit before Interest & Exceptional items	2,620.66	1,583.53	1,725.30	5,845.21	4,557.22	6,741.04
6. Interest	372.62	337.16	345.93	994.73	1,216.26	1,565.82
7. Profit after Interest but before Exceptional Items	2,248.04	1,246.37	1,379.37	4,850.48	3,340.96	5,175.22
8. Exceptional items	-	-	-	-	-	-
9. Profit from Ordinary Activities before tax	2,248.04	1,246.37	1,379.37	4,850.48	3,340.96	5,175.22
10. Tax Expense	397.21	61.00	184.51	561.21	443.06	530.68
11. Net Profit from Ordinary Activities after tax	1,850.83	1,185.37	1,194.86	4,289.27	2,897.90	4,644.54
12. Extraordinary items (net of tax expense)	-	-	-	-	-	-
13. Net Profit for the period	1,850.83	1,185.37	1,194.86	4,289.27	2,897.90	4,644.54
14. Paid-up Equity Share Capital (Face value of ₹10/- each)	1,179.61	1,179.61	1,179.61	1,179.61	1,179.61	1,179.61
15. Reserve excluding Revaluation Reserve	NA	NA	NA	NA	NA	20,375.21
16. Earnings Per Share (EPS)						
Basic and diluted (not annualised) - ₹	15.81	10.12	10.21	36.63	24.75	39.67
17. Public Shareholding						
- Number of shares	3,638,644	3,884,879	3,884,879	3,638,644	3,884,879	3,884,879
- Percentage of shareholding	31.08%	33.18%	33.18%	31.08%	33.18%	33.18%
18. Promoters and promoter group shareholding						
a) Pledged/Encumbered						
- Number of shares	550,000	200,000	200,000	550,000	200,000	200,000
- Percentage of total promoter's holding	6.82%	2.56%	2.56%	6.82%	2.56%	2.56%
- Percentage of total share capital of company	4.70%	1.71%	1.71%	4.70%	1.71%	1.71%
b) Non-encumbered						
- Number of shares	7,519,856	7,623,621	7,623,621	7,519,856	7,623,621	7,623,621
- Percentage of total promoter's holding	93.18%	97.44%	97.44%	93.18%	97.44%	97.44%
- Percentage of total share capital of company	64.22%	65.11%	65.11%	64.22%	65.11%	65.11%

Notes :

- Above results have been reviewed by Audit Committee and approved by Board of Directors at their meeting held on 24th January 2012
- Statutory Auditors have carried out Limited Review of the above results.
- The company has one segment of activity namely, pharmaceuticals.
- Investor's Complaints status - Opening - 0, Received - 2, Resolved - 2, Closing - 0.
- During the quarter, 30,000 stock options were granted to eligible employees under ESOS 2011
- Previous period's figures have been regrouped wherever necessary.

By order of the Board
For Ajanta Pharma Ltd.

Yogesh M. Agrawal
Managing Director

Mumbai, 24th January, 2012



COMPANY CONTACT:

Ajanta House,
Charkop, Kandivli (West),
Mumbai – 400 067
+91 22 66061000
www.ajantapharma.com

INVESTOR CONTACTS:

Deodatta Pandit
Company Secretary
+91 22 66061203
deodatta.pandit@ajantapharma.com

Press Release

Ajanta Pharma Achieves Excellent Growth Q3 Profit After Tax up 55%

Mumbai – (January 24, 2012) – Ajanta Pharma Limited, a specialty focused pharmaceutical formulation company, has posted 55% increase in net profit for the third quarter of FY 2011-12. The Profit after Tax stood at Rs. 18.51crores (Rs.11.95crores) for the quarter ended December 31, 2011. Net sales for the quarter stood at Rs. 163.90crores (Rs.120.51crores), an excellent growth of 36% over same period of previous year. Profit After Tax for the nine months ended December 31, 2011 stood at Rs. 42.89crores against Rs.28.98crores last year same period, a growth of 48%. Net sales for the nine months stood at Rs.426.34crs. (Rs.331.30crs.), a growth of 29% for the period.

Commenting on results, Mr. Yogesh Agrawal, Managing Director, Ajanta Pharma Limited said “We are pleased with our all rounded Q3 performance in terms of sales and profits. In Indian market, with strong thrust, we continue to build leadership positions in the sub-therapeutic areas into the speciality segments. In International markets, we continue our focus on select countries with wider product portfolio building into sustainable and profitable business.”

In order to meet the growing market demand, company shall be adding additional manufacturing capacities in coming year which will be funded through internal accrual and debt. In USA, company has already obtained the approval for 2 ANDA’s and expect to start the sales into US by Q1 of next year for the same. Besides the 2 approved ANDA’s, company has already filed 5 ANDA’s with US FDA which are under review. Company expects to file another 3 ANDA’s in Q4 of the current year with US FDA. “Steadily, we are building our ANDA portfolio in the US market which shall assure sustained growth in coming years” he said.

About Ajanta pharma

Ajanta Pharma is a speciality pharmaceutical formulation company, having leading brands in the therapeutic segments of Ophthalmology, Dermatology and Cardiology. Many of the company’s products are first of its kind and are leading in their sub therapeutic segments. Company exports its products to more than 25 countries and established strong brand equity in these markets. For last 10 years, company’s consolidated performance has been excellent with CAGR of 21% in sales and 37% in net profit.

Ajanta Pharma has its State of the Art R&D centre located at Mumbai, with more than 200 scientists working for formulation development. The company has world class manufacturing facilities - four located in India and one at Mauritius. One of the manufacturing facilities at Aurangabad is approved by US FDA, UK MHRA and World health organisation (WHO), apart from having the approval from FDA of many other countries.

